Assembly Biosciences terminates license agreement with Indiana University for HBV program

ASSEMBLY BIOSCIENCES, INC.

On January 11, 2024, Assembly Biosciences notified IURTC of termination of exclusive license for HBV patents including vebicorvir (VBR).
Termination effective April 11, 2024, 90 days after notice; VBR development was discontinued in July 2022.
Aggregate milestone payments under the license were $0.8 million; royalties ranged from 0.5% to 1.75% on net sales.
Annual diligence maintenance fees of $0.1 million were paid, creditable against milestone payments.
Next-generation capsid assembly modulators (CAMs) were internally discovered and not covered by the terminated license.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. terminated Exclusive License Agreement with Indiana University Research and Technology Corporation (effective 2024-01-11).

Action: termination
Agreement: license
Counterparty: Indiana University Research and Technology Corporation
Effective: 2024-01-11

Exact text from the filing

On January 11, 2024, Assembly Biosciences, Inc. (the "Company") notified the Indiana University Innovation and Commercialization Office that the Company has decided to terminate the Exclusive License Agreement dated September 3, 2023 by and between Indiana University Research and Technology Corporation ("IURTC") and Assembly Pharmaceuticals, Inc., the Company's predecessor (the "License Agreement"), as amended by Amendment No. 1 to the License Agreement dated February 28, 2017 and Amendment No. 2 to the License Agreement dated July 10, 2020.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-005024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.